<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9319162</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2572</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Opin Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr. Opin. Neurol.</journal-id>
<journal-title-group>
<journal-title>Current opinion in neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1350-7540</issn>
<issn pub-type="epub">1473-6551</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28141738</article-id>
<article-id pub-id-type="pmc">5409832</article-id>
<article-id pub-id-type="doi">10.1097/WCO.0000000000000432</article-id>
<article-id pub-id-type="manuscript">NIHMS856759</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>New insights into the mechanisms of the ketogenic diet</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Boison</surname>
<given-names>Detlev</given-names>
</name>
<aff id="A1">Robert Stone Dow Neurobiology Laboratories, Legacy Research Institute, Portland, Oregon, USA</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="FN1">Correspondence to Detlev Boison, PhD, Robert Stone Dow Neurobiology Laboratories, Legacy Research Institute, 1225 NE 2<sup>nd</sup> Ave, Portland, OR 97232, USA, Tel: +1 503 413 1754; fax: +1 503 413 5465, <email>dboison@downeurobiology.org</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>Conflicts of interest</bold>
</p>
<p>The author has no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>23</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>4</month>
<year>2018</year>
</pub-date>
<volume>30</volume>
<issue>2</issue>
<fpage>187</fpage>
<lpage>192</lpage>
<!--elocation-id from pubmed: 10.1097/WCO.0000000000000432-->
<abstract>
<sec id="S1">
<title>Purpose of review</title>
<p id="P1">High-fat, low-carbohydrate ketogenic diets (KDs) have been used for almost a century for the treatment of epilepsy. Used traditionally for the treatment of refractory pediatric epilepsies, in recent years the use of KDs has experienced a revival to include the treatment of adulthood epilepsies as well as conditions ranging from autism to chronic pain and cancer. Despite the ability of KD therapy to suppress seizures refractory to antiepileptic drugs and reports of lasting seizure freedom, the underlying mechanisms are poorly understood. This review explores new insights into mechanisms mobilized by KD therapies.</p>
</sec>
<sec id="S2">
<title>Recent findings</title>
<p id="P2">KDs act through a combination of mechanisms, which are linked to the effects of ketones and glucose restriction, and to interactions with receptors, channels, and metabolic enzymes. Decanoic acid, a component of medium chain triclycerides, contributes to seizure control through direct AMPA receptor inhibition, whereas drugs targeting lactate dehydrogenase reduce seizures through inhibition of a metabolic pathway. KD therapy also affects DNA methylation, a novel epigenetic mechanism of the diet.</p>
</sec>
<sec id="S3">
<title>Summary</title>
<p id="P3">KD therapy combines several beneficial mechanisms that provide broad benefits for the treatment of epilepsy with the potential to not only suppress seizures but also to modify the course of the epilepsy.</p>
</sec>
</abstract>
<kwd-group>
<kwd>metabolism</kwd>
<kwd>ketones</kwd>
<kwd>seizure suppression</kwd>
<kwd>epileptogenesis</kwd>
<kwd>epigenetics</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>